BridgeBio Reports Operating Loss Last Year... 4.9 Billion Won Capital Increase
[Asia Economy Reporter Ji Yeon-jin] BridgeBio (BridgeBio Therapeutics) announced on the 23rd that its consolidated sales for last year amounted to 6.3 billion KRW, a decrease of 89.1% compared to the previous year. Operating loss and net loss for the period turned to deficits, recording 19.5 billion KRW and 19.2 billion KRW, respectively.
The company also decided to raise capital through a third-party allotment of 317,460 common shares to secure operating funds. The issuance price per common share is 15,750 KRW, totaling approximately 4.9 billion KRW.
Hot Picks Today
![[Breaking] Samsung Electronics Management: "The Principle That Rewards Are Given Where There Are Results Has Been Upheld"](https://cwcontent.asiae.co.kr/asiaresize/93/2026052014513970767_1779256299.png)
[Breaking] Samsung Electronics Management: "The Principle That Rewards Are Given Where There Are Results Has Been Upheld"
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
To increase BridgeBio's capital, it was announced that 10,000 shares of its U.S. subsidiary BridgeMyotherapeutics were acquired for 11 billion KRW.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![[Breaking] Samsung Electronics Labor and Management Officially Sign Tentative Agreement](https://cwcontent.asiae.co.kr/asiaresize/307/2026052022492353201A.jpg)
